High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.

[1]  P. Ridker,et al.  Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial , 2015 .

[2]  W. Kraus,et al.  A Guide for a Cardiovascular Genomics Biorepository: the CATHGEN Experience , 2015, Journal of Cardiovascular Translational Research.

[3]  K. Rye,et al.  HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. , 2015, Circulation research.

[4]  Jun Liu,et al.  Cholesterol-overloaded HDL particles are independently associated with progression of carotid atherosclerosis in a cardiovascular disease-free population: a community-based cohort study. , 2015, Journal of the American College of Cardiology.

[5]  M. Carnethon,et al.  Lipoprotein Particles and Incident Type 2 Diabetes in the Multi-Ethnic Study of Atherosclerosis , 2015, Diabetes Care.

[6]  A. Khera,et al.  HDL cholesterol efflux capacity and incident cardiovascular events. , 2014, The New England journal of medicine.

[7]  R. Sacco,et al.  High-density lipoprotein subfractions and carotid plaque: the Northern Manhattan Study. , 2014, Atherosclerosis.

[8]  D. Rader,et al.  HDL and cardiovascular disease , 2014, The Lancet.

[9]  M. Banach,et al.  Subfractions and subpopulations of HDL: an update. , 2014, Current medicinal chemistry.

[10]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[11]  S. Martin,et al.  High-density lipoprotein subfractions: current views and clinical practice applications , 2014, Trends in Endocrinology & Metabolism.

[12]  T. Hatsukami,et al.  HDL‐3 is a Superior Predictor of Carotid Artery Disease in a Case‐Control Cohort of 1725 Participants , 2014, Journal of the American Heart Association.

[13]  Pierre Coste,et al.  Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score , 2014, BMJ Open.

[14]  N. Paynter,et al.  High-Density Lipoprotein Particle Subclass Heterogeneity and Incident Coronary Heart Disease , 2014, Circulation. Cardiovascular quality and outcomes.

[15]  P. Ridker,et al.  High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy , 2013, Circulation.

[16]  Markus Abt,et al.  Effects of dalcetrapib in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.

[17]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[18]  Samia Mora,et al.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). , 2012, Journal of the American College of Cardiology.

[19]  R. Collins,et al.  Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.

[20]  D. Waters,et al.  Determinants of Residual Risk in Secondary Prevention Patients Treated With High- Versus Low-Dose Statin Therapy: The Treating to New Targets (TNT) Study , 2012, Circulation.

[21]  William Weintraub,et al.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.

[22]  Ming-Dauh Wang,et al.  Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. , 2011, JAMA.

[23]  A. Kontush,et al.  Biological activities of HDL subpopulations and their relevance to cardiovascular disease. , 2011, Trends in molecular medicine.

[24]  R. Krauss,et al.  HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. , 2011, Clinical chemistry.

[25]  V. Kakkar,et al.  Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response , 2010, Cholesterol.

[26]  W. Kraus,et al.  Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. , 2010, American heart journal.

[27]  M. Reilly,et al.  Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. , 2009, American heart journal.

[28]  R. Karas,et al.  Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. , 2009, Journal of clinical lipidology.

[29]  N. Wareham,et al.  High-Density Lipoprotein Particle Size and Concentration and Coronary Risk , 2009, Annals of Internal Medicine.

[30]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[31]  G. Fonarow,et al.  The paradox of dysfunctional high-density lipoprotein , 2007, Current opinion in lipidology.

[32]  D. Grobbee,et al.  Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. , 2007, The New England journal of medicine.

[33]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[34]  W. Cromwell,et al.  Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. , 2006, Clinics in laboratory medicine.

[35]  K. Eagle,et al.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.

[36]  H. Bloomfield,et al.  Low-Density Lipoprotein and High-Density Lipoprotein Particle Subclasses Predict Coronary Events and Are Favorably Changed by Gemfibrozil Therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial , 2006, Circulation.

[37]  J. Yarnell,et al.  High density lipoprotein subfractions and the risk of coronary heart disease: 9-years follow-up in the Caerphilly Study. , 2003, Atherosclerosis.

[38]  G. Dagenais,et al.  Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Québec Cardiovascular Study. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[39]  P. Elwood,et al.  Associations of the HDL2 and HDL3 Cholesterol Subfractions With the Development of Ischemic Heart Disease in British Men: The Caerphilly and Speedwell Collaborative Heart Disease Studies , 1994, Circulation.

[40]  W. Willett,et al.  A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. , 1991, The New England journal of medicine.

[41]  P. Joshi,et al.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. , 2015, European heart journal.

[42]  B. De Geest,et al.  Therapeutic potential of HDL in cardioprotection and tissue repair. , 2015, Handbook of experimental pharmacology.

[43]  G. Franceschini,et al.  HDL and atherosclerosis: Insights from inherited HDL disorders. , 2015, Biochimica et biophysica acta.

[44]  Atta-ur-rahman.  First issue of 2014, Current Medicinal Chemistry. , 2014, Current Medicinal Chemistry.